YORK, Pa., Sept. 12, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced the development of its AutoInfusor portfolio of subcutaneous infusion systems for the patient self-administration of drugs in 3mL, 5mL, 7mL, and 10mL volumes.
Unilife has developed its AutoInfusor technology to address the unmet needs of pharmaceutical and biotechnology companies with drugs that have complex formulations with higher viscosities and requiring large dose volumes. AutoInfusors are now available for supply to pharmaceutical companies for human clinical trials in either prefilled or fill-at-time-of-use formats.
AutoInfusors are compact, single-use drug delivery systems that are designed for simple, intuitive and convenient use by patients outside of healthcare facilities. Consisting of a primary drug container, fluid delivery path, and drive mechanism, AutoInfusors are modular in design and can be customized to address the specific requirement of the drug and its target patient. They can be pre-set for infusion periods that can span minutes or hours in duration, as specified by the pharmaceutical customer.
Once the patient attaches the device onto the injection site and pushes the activation button, the automatic infusion of the drug into the subcutaneous tissue commences. With the size, shape and functionality of the AutoInfusor being ergonomically designed for optimal wearability, the patient can continue to go about their normal daily routines during the period of dose delivery. A series of audible, tactile and visual indicators can signal to the patient when the full dose has been delivered, at which time the AutoInfusor can be removed from the body for convenient disposal.
Mr. Alan Shortall, CEO of Unilife said, "Our AutoInfusors represent the world's first and only subcutaneous infusion system ready for human clinical trials that can facilitate the patient self-administration of drugs between 3mL and 10mL in dose volume.
"Pharmaceutical companies are actively developing a significant number of pipeline drugs targeted for the treatment of acute, chronic and palliative diseases. Many of these emerging macro-molecule drugs, including a number of biologics, feature a complex formulation of proteins with higher viscosities that require large volume doses. The conventional patch pumps that have been developed for the delivery of drugs such as insulin are largely unsuitable for delivery of these drugs. Until now, pharmaceutical companies developing these complex drugs have lacked access to a single-use subcutaneous infusion system that can enable patients to easily self-administer doses greater than 3mL in volume.
"As the world's first and only known subcutaneous infusion systems available in a range of sizes including 3mL, 5mL, 7mL, and 10mL, our AutoInfusors represent breakthrough technology within this fast-growing and high-value sector for injectable drug delivery devices. For clinical trial purposes, the AutoInfusor can either be filled at the time of use for the convenience of pharmaceutical customers, or supplied in a prefilled format.
"With the development of our AutoInfusor technology platform, Unilife now has the most complete proprietary portfolio of injectable drug delivery devices. Our extensive and customer-focused portfolio of technology platforms includes our Unifill primary drug delivery systems with integrated safety features, patient self-injection devices including auto-injectors and subcutaneous infusion systems, as well as devices for targeted organ delivery. With Unilife, pharmaceutical and biotechnology companies now have the option of selecting a single partner in the development and commercial supply of innovative, differentiated devices that can help to enable, enhance and extend the commercial lifecycles of their injectable drugs and vaccines."
Pharmaceutical and biotechnology companies seeking additional information regarding the Unilife AutoInfusor can contact Unilife at email@example.com.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs. For more information on Unilife, please visit www.unilife.com
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Investor Contacts (US):
Investor Contacts (Australia)
Todd Fromer / Garth Russell
KCSA Strategic Communications
Carpe DM Inc
P: + 1 212-682-6300
P: + 1 908 469 1788
P: + 61 2 8346 6500
SOURCE Unilife Corporation